Romosozumab

4 trials 2 recruiting MMusculoskeletal

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

1 Completed trials

3 Sponsors

10 Countries

Phase III

Phase III/IV

Phase IV

Phase III: 2 Phase III/IV: 1 Phase IV: 1

Indications tested

Osteogenesis imperfecta 2 Osteoporosis postmenopausal 1

Sponsors using this IMP

Amgen Inc. 2 Aarhus University Hospital 1 Ospedale Galeazzi S.p.A. 1

All trials

4 total

ATRIO Study: Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporosis: A Phase IV, Low-Risk Int… Pending

2025-522592-29-00 Phase IV 1 country Ospedale Galeazzi S.p.A.
Pediatric Safety Follow-up Study of Prior Treatment with Romosozumab for Osteogenesis Imperfecta Recruiting

2023-503293-21-00 Phase III 7 countries Amgen Inc.
The OPTIMIST study Recruiting

2023-505940-20-00 Phase III/IV 1 country Aarhus University Hospital
A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Chi… Ended

2023-503294-37-00 Phase III 9 countries Amgen Inc.

Showing 1–4 of 4 trials

← All drugs A–Z